Replies to post #101366 on Biotech Values

[RockRat]

"Since FDA approval, sales that may be presumed to be tax-related, at least in
part, have been made by Wheeler, Venkataraman, Brugger, and Bishop
at prices between 17.20 and 24.48. "

I'm not seeing any change in Bishop's position in the three tables you've recently posted.

Not that it's a big deal.

Regards, RockRat

[DewDiligence]

MNTA Insider Shareholdings

[Updated for SEC filings through 8/26/10.]


FDA approval of generic Lovenox on 7/23/10 triggered the vesting of
restricted shares held by MNTA’s executive officers, which incurred
an income-tax liability for these officers (#msg-53029172). On the
2Q10 CC on 8/3/10, CFO Rick Shea disclosed that officers would be
selling shares to cover their tax liability from the newly vested shares.
In addition, all of the executive officers and two of the directors have
10b5-1 plans that generate small sales on a regular basis.

The table entries below include both ordinary and restricted shares
and both vested and non-vested options.

 
                             Shares    Options 
 Officers 
 *Craig Wheeler (CEO)       344,610    675,000 
 *G Venkataraman‡ (SVP/R&D) 341,887    189,325 
 *Steven Brugger (COO)      209,645    246,194 
 *John Bishop (SVP/Pharma)   49,239    121,860 
 *Richard Shea (CFO)         39,951    249,200 
 *Bruce Leicher (Gen Cnsl)   38,780    137,050 
 *James Roach (CMO)          18,032    205,250 
  
 Directors 
 John Clarke                 77,123    126,000 
 Bruce Downey†                    0     45,000 
 Marsha Fanucci                   0    126,000 
 Peter Hutt                  67,863    201,500 
 *Ram Sasisekharan‡         306,344    126,000 
 *Bennett Shapiro             7,000    140,450 
 Elizabeth Stoner                 0     79,200 
 James Sulat (Chairman)           0     60,000 
 ======================   =========  ========= 
 All fifteen insiders     1,500,474  2,728,029 
  
 *10b5-1 selling plan in effect. 
 †Joined BoD 6/11/09. 
 ‡Co-founder.